{"nctId":"NCT02023268","briefTitle":"Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome","startDateStruct":{"date":"2013-12"},"conditions":["Dry Eye Syndrome"],"count":105,"armGroups":[{"label":"T2762","type":"EXPERIMENTAL","interventionNames":["Device: T2762"]},{"label":"Vismed®","type":"ACTIVE_COMPARATOR","interventionNames":["Device: Vismed®"]}],"interventions":[{"name":"T2762","otherNames":[]},{"name":"Vismed®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed and dated informed consent\n* Male or female aged from ≥ 18 years old.\n* Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior to study selection.\n\nExclusion Criteria:\n\n* Best far corrected visual acuity \\< 1/10\n* Severe blepharitis\n* Severe Dry Eye","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Global Ocular Staining (With Oxford Scale - Ranges : 0-15)","description":"Change from Baseline in the worse eye on Day 35 (decrease of Oxford score = better outcome)\n\nGlobal Ocular Staining With the Oxford Scale measured surface damage to treated eyes(by T2762 or vismed).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"2.0"},{"groupId":"OG001","value":"-2.7","spread":"1.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":[]}}}